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While not yet validated for the pediatric or adult HSCT population, serum citrulline levels appear to be an appropriate and accurate measure of morbidities following myeloablative therapy. [1] [2] [3] [4] [5] Chemotherapy induces a decrease in citrulline levels, 1, 2, 6 and citrulline has also been found to correlate with the radiation dose received and volume of bowel in the field of radiation. 1, 7, 8 In a pilot study of nine pediatric patients with AML undergoing chemotherapy, citrulline showed the strongest correlation with clinical mucositis scales. 9 This study aimed to determine whether citrulline levels correlate with clinical markers of intestinal injury in children undergoing a myeloablative allogeneic transplant regimen. Secondary aims included collecting reference values for this population, investigation of associations between the prevalence of infections and acute GVHD and citrulline, and the effect of TBI on citrulline levels.
Children and adolescents between 2 and 21 years old undergoing myeloablative allogeneic (matched, unrelated or sibling matched) SCT at New York Presbyterian Hospital-Columbia University Medical Center were eligible for participation in the study. The study was approved by the institutional review board.
Stem cell sources included BM, umbilical cord blood or cytokine-mobilized peripheral blood. Donors could be HLA matched, sibling, or parent, a related donor mismatched for a single HLA locus (class I or II), unrelated marrow or PBSC donor, or unrelated cord blood at least 4/6 antigen match (class I or II). Exclusion criteria included patients with renal insufficiency or with any type of chronic disease leading to intestinal damage. 5 Serum citrulline levels, oral mucositis scores and intestinal toxicity/GVHD scores were collected on days À 1, 0, þ 3, þ 7, þ 14 and þ 21 of transplant regimen. Blood samples were collected ± 24 h from each timepoint. Demographics and clinical data were collected from the medical record.
Citrulline levels were summarized at each timepoint. Change over time and the relationship between citrulline and mucositis, diarrhea, bacteremia and GVHD was assessed by a generalized estimating equation (GEE) approach. The Exact Wilcoxon test was used to assess the difference in citrulline levels between participants who did or did not receive TBI. Analysis was performed in SAS 9.2. Table 1 shows study population demographics of the participants. Ten patients were recruited to the study with 60% receiving TBI. Average citrulline values before treatment initiation was 20.1 mmol/L (Figure 1 ). The citrulline level decreased an average of 0.17 mmol/L (s.e. ¼ 0.11, P ¼ 0.11) per day of transplant regimen.
Associations between mean citrulline levels and treatment morbidities were examined. For every 1 mmol/L increase in citrulline, the odds of developing mucositis were 0.88 (95% confidence interval (CI) ¼ 0.79-0.99, P ¼ 0.036). In addition, the odds of developing diarrhea were 0.70 times less for every 1 mmol/L increase in citrulline (95% CI ¼ 0.59-0.84, Po0.0001). Interestingly, TBI was not associated with citruilline levels at every timepoint.
Citrulline levels were significantly lower in the TBI group compared to the no TBI group only on days þ 3 and þ 7 (P ¼ 0.008 and 0.005, respectively).
This pilot study demonstrated that plasma citrulline levels are a potentially accurate and minimally invasive strategy to measure intestinal mucosal toxicity. Average citrulline values decreased sharply within the first day of sampling (day À 1), found a nadir at day þ 7 and did not fully recover to previous values by day þ 21. Increased prevalence of mucositis and diarrhea were significantly associated with decreases in plasma citrulline levels. Administration of TBI was significantly associated with a greater reduction in citrulline values within the first week of transplant regimen.
The course of citrulline levels within the transplant regimen in our study was congruent with previously reported data among adults undergoing myeloablative therapy.
3,5 Citrulline levels did not recover within 3 weeks, much like a pattern seen in adults undergoing various myeloablative treatments. 4 The resemblance to these previous studies may suggest that absolute plasma citrulline is a reproducible and clinically useful biomarker in various populations.
This study was the first to report on changes in citrulline levels in children undergoing HSCT. The observed levels in our study can be roughly compared to a previously reported average reference values of 30 mmol/L for healthy children at both ages of 6 and 16 years. 10 The results from this small pilot study suggest that marked decreases in citrulline levels may be used to interpret gastrointestinal complications and to identify at-risk patients. Further investigations into citrulline could determine threshold values for early supportive care interventions including prophylactic medications and/or symptom management.
We found that decreases in citrulline levels were only significantly associated with mucositis and diarrhea. In addition, previous adult studies have also shown that low citrulline was associated with bacteremia. 3 The current study did find that the nadir of citrulline levels coincided with a peak in mucositis and diarrhea prevalence, a previously reported pattern among adults receiving HSCT. 2 Further studies investigating these correlation may elucidate the relationship between the biochemical and clinical phenomenon.
The use of TBI during the transplant regimen was associated with a greater decrease in citrulline levels during days þ 3 and þ 7, suggesting that TBI may increase vulnerability to gastrointestinal toxicity. In our study, citrulline was significantly associated with TBI, but showed no association with infections. Citrulline may be clinically valuable for differentiating between the multiple mechanisms of gastrointestinal symptomatology in pediatric HSCT patients, including myeloablative treatment, radiation and infections.
This study supports findings in the adult population that citrulline may be an appropriate indicator of enterocyte toxicity during a HSCT regimen. Specifically, decreases in citrulline are associated with increased odds of oral mucositis and diarrhea in pediatric patients undergoing myeloablative allogenic transplant. Further research can continue elucidate this relationship and investigate the use of plasma citrulline levels to anticipate and/or monitor gastrointenstinal complications in the HSCT pediatric population. Plasma citrulline values by day of transplant regimen. The greatest decrease in mean plasma citrulline occurred between days À 1 and 0 (13.0 mmol/L ). Mean citrulline level reached a nadir at day þ 7 (6.6 mmol/L) and did not fully recover by day þ 21, reaching about 50% of initial mean level. After myeloablative treatment initiation, absolute minimum value was 0 mmol/L in two patients and absolute maximum value was 16 mmol/L, both in two patients.
